Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04905875
Other study ID # 22/21
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 1, 2020
Est. completion date May 1, 2022

Study information

Verified date May 2021
Source St. Bortolo Hospital
Contact Silvia De Rosa, MD
Phone +393933098583
Email derosa.silvia@ymail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

SARS-CoV-2 infection is characterized mainly by moderate/severe pneumonia associated with progressive endothelial damage and coagulopathy. Acute respiratory failure among COVID-19 occurs in 42% of patients with COVID-19 pneumonia, and 61-81% of patients requiring intensive care . Among the suggested treatments for the management of ARDS patients, prone position (PP) can be used as an adjuvant therapy for improving ventilation in these patients, as recommended in the Surviving Sepsis Campaign COVID-19 guidelines. Nevertheless, no data is currently available on application and feasibility of PP in invasively ventilated patients with COVID-19 on their outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date May 1, 2022
Est. primary completion date May 1, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Laboratory-confirmed COVID-19 infection - Prone positioning in patients admitted to ICU undergoing invasive Mechanical Ventilation Exclusion Criteria: - Bedsides contraindications to the Prone Positioning and patients in PP but undergoing Non- invasive ventilation should be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Prone Position
Every center will prescribe PP in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.

Locations

Country Name City State
Italy Silvia De Rosa Vicenza

Sponsors (1)

Lead Sponsor Collaborator
St. Bortolo Hospital

Country where clinical trial is conducted

Italy, 

References & Publications (3)

Carsetti A, Damia Paciarini A, Marini B, Pantanetti S, Adrario E, Donati A. Prolonged prone position ventilation for SARS-CoV-2 patients is feasible and effective. Crit Care. 2020 May 15;24(1):225. doi: 10.1186/s13054-020-02956-w. — View Citation

Coppo A, Bellani G, Winterton D, Di Pierro M, Soria A, Faverio P, Cairo M, Mori S, Messinesi G, Contro E, Bonfanti P, Benini A, Valsecchi MG, Antolini L, Foti G. Feasibility and physiological effects of prone positioning in non-intubated patients with acu — View Citation

Lucchini A, Bambi S, Mattiussi E, Elli S, Villa L, Bondi H, Rona R, Fumagalli R, Foti G. Prone Position in Acute Respiratory Distress Syndrome Patients: A Retrospective Analysis of Complications. Dimens Crit Care Nurs. 2020 Jan/Feb;39(1):39-46. doi: 10.10 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Identification of the subpopulation of critically ill patients that most benefits from prone positioning their intermediate surrogate endpoints. Identification of the subpopulation of critically ill patients with COVID-19 that most benefits from This subpopulation will be described using the baseline variables associated with a positive long-term patient's outcome. In particular baseline variables statistically associated through multivariable regression analyses with the patient's survival at hospital discharge will be identified and expressed with their Odds ratios, 95%CI and p-value through study completion, an average of 1 year
Secondary Description of the over-time variation of clinical variables during prone positioning this over-time variation will be expressed, for each variable, as a percentage variation compared with the baseline value (at the prone position initiation).static compliance of the respiratoty system will be assessed through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Suspended NCT04901676 - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04534478 - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Phase 4
Active, not recruiting NCT05002517 - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Phase 3
Completed NCT05008393 - Efficacy of PJS-539 for Adult Patients With COVID-19. Phase 2
Completed NCT04569877 - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia Phase 2
Not yet recruiting NCT05286255 - Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias Phase 1
Completed NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Completed NCT06113432 - CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study N/A
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting NCT04615429 - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19 Phase 2
Completed NCT05047653 - RALE Versus CORADS/CT-Severity Score in COVID-19
Active, not recruiting NCT05047016 - Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY N/A
Active, not recruiting NCT05033847 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 2
Recruiting NCT06113757 - Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease N/A
Completed NCT05504655 - N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
Active, not recruiting NCT05035524 - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19 N/A
Completed NCT05065879 - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes Phase 4
Withdrawn NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Withdrawn NCT04460105 - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia Phase 1
Suspended NCT04901689 - Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation Phase 3

External Links